Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITACO and ITACO-ATI study guided by molecular HIV-1 reservoir profiling
2022-001437-36Phase 3Active
- Sponsor
- Ospedale Pediatrico Bambino Gesù
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of bictegravir + emtricitabine + tenofovir alafenamide in Human immunodeficiency virus infection type 1 and human immunodeficiency virus infection (HIV) (2 cohorts), sponsored by Ospedale Pediatrico Bambino Gesù. Primary endpoint: Primary endpoints - ITACO cohort. Started May 2022; status: active.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2022-001437-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001437-36.